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~,~thods: AMI pabents presenting ~t 1529 US hospitals wero enrolled 
in tho National Rogistry of Myocardial Infa~ion (NRMI-2) from 7/1194 to 
12/31/96 IS was defim~ as a focal neurological deficit due to confirmod 
ischomi¢ brain infarction In unadiustod analyses, temporal trond~, m d=flor. 
enoL~ in rate of and ouIcomo from IS in pstients who d~l (T) or did not (NT) 
receive thrombolyttc therapy were so.~ght, 
Results: 0! 445,!48 NRMI-~ p~tte~ts. 130.6~9 (294%) received throm- 
b0~i¢ therapy. Them were 3950 (0,89%) IS ,~n age 71.5 yeats), IS 
rate w~ Sig~flCardty lo~r  in T I~lt~l~ts han in ~ patlen~ (overall 0.63% 
~.  1.00%, p ~ 0001; l~me pe~:  T.0~53% ~ 7-1~ VIL 0,75% from 
7-12/94o ~,  re~q~n; NT ,O,~ from 7-1~ v~, 114% from 7~1~,  
~% r~dt.l¢1~t; allp .: 0,001), IS-associated ~Otlalily was s~f¢'antlY lower 
in T I~l~ntS than in NT Ip~f l ts  (26.9% VS, ~14,~, p .~ O001)~ 
Cohort,s/OraL" The rat~ ot !,~ ~ ~ ~ad~,l!y and slgndmanlly 
over time m ~ T and NT patmms, The fining° Of reduced IS rate and 
IS~ssOO~ ated moffahty rate over time in T patients suggest a benefit 
ot thmmb~ therapy for AMI on !S wevent~n_ 
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$C Sm~, Medial F~,w ol Nerth Car~ Ca~ NC, USA 
To further ~ r  the cocz~rovemy ~amrmg the retalKm between ca~cmm 
chan~ Uock~g drugs (CCSs) and mo~,  ~k~**ng acute myocard~a~ 
mfa~ (M|), we e~ammeO I year modatdy for 177.383 ekferty pahe~s 
according lo treatment w~h CCBs On cf~:harcje (HCFA's Coope~ Car- 
dm~ascubr ~ t~4-S).  The 57,822 ~ dL~-'hargml on CCBs (~m- 
azem 23.821, nded~me 14,162, amto0Tq3me 12.720, verapan'~i 4,040, other 
3,079) were shgt¢~y order, mote h~e~ to be women~ and have prim comna~ 
c~sease, hypettensto~ and non Q-~.~ myocardial infarctions. C~ I year 
mo~a~ty was foyer fo~ ~1 CCB types except bep~l  After risk adjustment 
(demographics_ contrary ~s ,e  and MI seventy, and con~rb~ dtness) ac- 
coring to a ipm~wts~, scorn, ip~ents treate~ with CCBs had k~wer 30 day 
lrelatn~ r~k 0.67 P - 0001) and 1 year mortahty ffefatwe risk 085 P • 
o 0os). 
t 2 3 4 5 
3~ ~,av CC~ 46 33 36 34 29 
moc'.~P,~ % ~ CCB 78 55 5 3 4 4 4 1 
I ~-~-3~ CCB 27 ~ 27 8 2~ 4 L ~) 1 30 3 
m.~t'tahtv % noCCB ,344 326 3~33 3.$2 345 
Thus, cont:ary to prev~ meta-a~a~/ses, we ta~lecl to find an association 
between calcium blocker therapy and mortality toflowmg acute Mi rn a large 
cohorl o! elderly patfents 
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~;arolovascurar Uu1¢omes In thQ ChOlesterol and 
Rocurmnt Eventm (CARE) Trial 
V, Papadememog. D Na~h. P, Narayan. B, Daws, L, $~mpson, G Mara~s, 
J~ Rouleau, F Sacks, Institute O~ CaK~ogte, H~rt~ Sct~ol ot Put~c 
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~gfound: .  Th~ Main tabu!Is of the CARE trial have been I~Vm~Sty 
I,~hed (NE=JM, 1996: 335: 101~9), The puq~oee of the present analysm was 
to assess the assoctatfon Of¢a~1¢i1~'~ cham';~t t~¢kef (CCB) t ~  w,~h 
otltcomes 
Methoo~ Ot the 4,159 paft~q~t~ofs, m~zed an av of 10 too, post MI, 
1,648 (39,6%) were treated at base!i~ w~ CCB (av age 59.0 ~ 92 Y~) 
& 2,5!1 were not (No CCB ~ age 58.4 ~_ 9,4 Yl~S), C0mpanson.s betwee~ 
gfo~ were made using ¢ht sq.. unwanate & muflwanate a~lysm, 
Results: At baseline pls On CCB had h~= ~VEF (54,1 vs 52.3%, p - 
00001), tetal ChOI (2096 v~ 20?.8 m~*dt; p 0 001), LDL,C (139.2 vs 1382 
mgtdl, p = 0.03), Hx of hyperlensm~ (49.1% vs 384%; p < 00001), ¢~etes 
metlltus 116.3 v'S t2,7%1 p ~ 00011. & Hx o1 PTCA (36(~ vs 21.7%; p < 
0,001 ), Fewer pts On CCB had Hs of CABG ( 12.0% vs 27 I~;  p < 00011, H~ 
0f CHF (5,7% vs 80%,~ p - 0.004). treatment with ACE Inhibltc,~ (11 6% vs 
16 3%; p ~ 0.001 ) o,z beta blockers (32.0% vs 45 5%, p ~ 0.001). Pravastatm 
therapy resulted In s~gndcant reduct~n of total choL & LDL cholesterol m bo~h 
groups but reductions were greater in the CCB group. At the end of the fo~k~ 
up penod after con~mlhng to, basehne d~terervces, patmnts on CCB had 55% 
h~]her incKlerme of PTCA (p ~ O.00t), 82% more CABG (p < 0.001), 64% 
more tmstabte arena (p ~: 0.001). 30% more CVS hospital=zatmns (p
0.0001) & 2.04 times the risk d GI bleed (p = o018). 
C ~ :  Use of CCBs is a marker of high nsk of recurrent card=ovas- 
cutar events in pts w~th acute MI 
